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Vascular endothelial growth factor-C (VEGF-C) and VEGF-D are members of the VEGF family of cytokines and have angiogenic and
lymphangiogenic actions. In gastric adenocarcinoma, VEGF-C mRNA and tissue protein expression correlate with lymphatic invasion,
lymph node metastasis and in some reports, venous invasion and reduced 5-year survival. Patients with gastric adenocarcinomas
containing high levels of VEGF-C expression have significantly reduced 5-year survival rates, and VEGF-C expression is an
independent prognostic risk factor for death. The role of VEGF-C in oesophageal squamous and colorectal cancer and VEGF-D in
colorectal cancer is not clear, with conflicting reports in the published literature. In order to exploit potential therapeutic applications,
further research is necessary to define the precise roles of these cytokines in health and disease.
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Lymphangiogenesis, the development of new lymph vessels, is a
relatively new area of clinical investigation. Increased interest in
this field has been heightened by the discovery of new vascular
endothelial growth factor (VEGF) family members, which possess
lymphangiogenic roles.
Vascular endothelial growth factor-C (VEGF-C) and VEGF-D are
secreted glycoproteins that are structurally similar, sharing areas
of homology with one another and with the angiogenic growth
factor VEGF-A (Joukov et al, 1996; Achen et al, 1998). They are
specific ligands for the tyrosine kinase receptor, vascular
endothelial growth factor receptor (VEGFR)-3 (flt-4) (Joukov
et al, 1996; Achen et al, 1998). Both cytokines are subject to
proteolytic processing, which also enables them to act as ligands
for VEGFR2 (KDR/flk-1) (Joukov et al, 1997; Stacker et al, 1999).
Vascular endothelial growth factor receptor 2 is expressed on
vascular endothelial cells and is essential for the embryonic
differentiation of endothelial and haematopoietic cells and
formation of blood vessels (reviewed in Veikkola et al, 2000).
Vascular endothelial growth factor receptor 3 is expressed on
vascular endothelium early in development and on angiogenic
endothelium, but is mainly restricted to the lymphatic endothe-
lium in the adult (Kaipainen et al, 1995). Consequently, VEGF-C
and D are implicated through their receptor affinities in angiogenic
and lymphangiogenic pathways in health and disease (Stacker et al,
2002).
ROLES OF VEGF-C AND VEGF-D
Study of the lymphatic system and lymphatic endothelial cells has
been limited by a lack of specific lymphatic vessel markers, lack of
lymphatic endothelial cells for culture and limited animal models.
These problems are currently being overcome with a variety of
methods. The recent discovery of specific lymphatic vessel
markers, such as the hyaluronan receptor LYVE-1, podoplanin
and Prox-1, new antibodies to these markers and antibody
combinations has aided the identification of lymphatic vessels in
histological specimens (Stacker et al, 2002) (Table 1). The
exploitation of the differential expression of these new specific
cell surface markers by lymphatic and blood vascular endothelial
cells has allowed the separation of stable lymphatic cell popula-
tions for study (Podgrabinska et al, 2002). Animal models have
been adapted from angiogenesis research and specific tumour,
transgenic and knock-out models developed.
Our current understanding of the roles of VEGF-C and VEGF-D
is derived mainly from in vitro and in vivo studies. In vitro studies
have shown that VEGF-C and VEGF-D exhibit mitogenic effects for
vascular and lymphatic endothelial cells and survival-promoting
abilities for lymphatic endothelial cells through VEGFR3 (Joukov
et al, 1997; Achen et al, 1998; Marconcini et al, 1999; Veikkola et al,
2001). Both growth factors promote angiogenesis in in vitro assays
(Joukov et al, 1996; Joukov et al, 1997; Marconcini et al, 1999).
Vascular endothelial growth factor-C promotes the formation of
capillary-tube structures by lymphatic endothelial cells, but not
blood vascular endothelial cells, in a collagen sandwich assay
(Podgrabinska et al, 2002).
In vivo studies, using models adapted from angiogenesis
research, have confirmed the angiogenic abilities of VEGF-C and
VEGF-D and the lymphangiogenic effect of VEGF-C (Oh et al, Received 16 January 2003; revised 13 May 2003; accepted 21 May 2003
*Correspondence: Dr SE Duff; E-mail: sarah.duff@christie-tr.nwest.nhs.uk
British Journal of Cancer (2003) 89, 426–430
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com1997). Transgenic mouse models, which overexpress VEGF-C or
VEGF-D in the epidermis, have shown cytokine-dependent,
VEGFR3-mediated dermal lymphatic vessel enlargement and
lymphatic endothelial cell proliferation without alteration in blood
vasculature (Jeltsch et al, 1997; Makinen et al, 2001; Veikkola et al,
2001). Various tumour models have been constructed in which
overexpression of VEGF-C or VEGF-D is demonstrated. These
studies consistently show increased aggressiveness of the
transfected cancer cell lines, intratumoural lymphangiogenesis,
dilated and increased numbers of peritumoural lymphatics,
enhanced rates of lymph node metastasis and increased tumour
angiogenesis (Karpanen et al, 2001; Mandriota et al, 2001; Skobe
et al, 2001).
Despite the implication of VEGF-C and VEGF-D in lymphangio-
genic and angiogenic pathways in these studies, the role of
the growth factors in the progression of human malignancy is
unclear and the existence of functional lymphatics and lymphan-
giogenesis in human malignancy has been debated (Leu et al, 2000;
Clarijs et al, 2001; Padera et al, 2002). Recent studies in head and
neck cancer (Beasley et al, 2002; Maula et al, 2003) and melanoma
(Straume et al, 2003) have demonstrated the existence of
proliferating intratumoral lymphatic vessels. Further research
is required to determine whether this is the case for all the
different human malignancies that spread predominantly by the
lymphatic route. The situation is likely to be clarified further
by the use of antibodies and antibody combinations for the
more specific lymphatic markers in conjunction with functional
assays.
VASCULAR ENDOTHELIAL GROWTH FACTOR-C AND
VEGF-D IN HUMAN MALIGNANCIES
The dissemination of malignant cells to the regional lymph nodes
is an early step in the progression of many common solid tumours
and is an important determinant of prognosis. Positive associa-
tions have been found between the expression of VEGF-C in
human malignant tissue with adverse clinicopathological features
including lymphatic invasion and lymph node metastasis. Expres-
sion of VEGF-C mRNA is increased in a variety of human
malignancies (Salven et al, 1998). Tumour types investigated
include breast, gastric, colorectal, oesophageal, prostate, pancreas,
cervical, thyroid, non-small-cell lung cancers, lung adenocarcino-
ma and laryngeal cancers. Clinically important areas of interest are
the association between VEGF-C and -D expression, intra- and
peritumoral lymphatic density, lymphatic and venous invasion,
lymph node metastasis and survival.
Methodological considerations
Many published reports conflict in their outcomes and conclu-
sions. This may be partly explained by the use of different
methodological tools and assumptions by their authors.
Immunohistochemical techniques and microvessel counting
examine the tissue as near its condition in vivo as possible. Even
so, results obtained examining malignant tissue at the invasive
edge of tumours may not concur with results from central and
superficial parts of the tumour (Furodoi et al, 2002). Scoring
methods for both immunohistochemical staining and vessel
counting vary between studies, with consequent difficulties in
the extrapolation of results. Furthermore, the subjective nature of
assessment of staining intensity and the frequent lack of positive
or negative tissue controls in immunohistochemical analyses can
confound analysis.
Studies examining mRNA levels provide an estimate of overall
expression in the tissue fragment analysed, including tumour cells,
stroma and normal mucosa, as RNA extraction necessarily entails
tissue disruption. The nature of the interaction between expressed
cytokines and the tumour microenvironment is at the cellular and
paracrine level (Furodoi et al, 2002). Consequently, analysis of
global tumour mRNA levels may miss subtleties of tissue
expression that are crucial for tumour behaviour. The expression
of mRNA in a tissue fragment may not necessarily equate with the
expression of protein by the tumour.
Evidence for tumour-related lymphangiogenesis is derived from
the presence of intratumoral lymphatics in xenograft studies.
However, these vessels may be trapped in the tumour mass as a
consequence of the methodology of model construction. Conse-
quently, studies involving transgenic animals overexpressing
VEGF-C, in which dilation of peritumoral lymphatics are seen
(Mandriota et al, 2001) may reflect the situation in spontaneously
arising human tumours more accurately (Karpanen and Alitalo,
2001).
Further discussion will focus on the current evidence for the role
of VEGF-C and VEGF-D and their signalling receptors for the
common sites of malignancy of the gastrointestinal tract (Table 2).
Gastric cancer
Gastric cancer is a leading cause of cancer death worldwide.
Lymph node status is important in the prediction of prognosis.
Potential molecular markers that predict lymphatic involvement
would improve the clinical management of this disease. The role of
VEGF-C in predicting lymphatic invasion and lymph node
metastasis in gastric cancer has been investigated in several
Table 1 Immunohistochemical staining methods for the detection of lymphatic endothelial cells
Sites of antigen expression Advantages Disadvantages
Single staining methods
VEGFR3 antibody LEC, tumour neovasculature LEC specific in normal tissue Lack of specificity in tumours, VEGFR3
upregulated in angiogenic endothelium
Podoplanin antibody LEC, glomerular podocytes LEC specific Lack of commercial antibody availability
Prox-1 antibody LEC LEC specific Lack of commercial antibody availability
LYVE-1 antibody LEC, hepatic sinusoidal cells LEC specific Lack of commercial antibody availability
Enzyme histochemistry (50NA activity) All endothelial cells at different levels Findings difficult to interpret
Hampered by nonspecific staining
Double staining methods
CD31/PAL-E antibodies Pan-EC marker/BEC Enhanced discrimination accuracy Frozen tissue required
VEGFR3/PAL-E antibodies LEC, angiogenic BEC/BEC Enhanced discrimination accuracy Frozen tissue required
LYVE-1/CD34 antibodies LEC/Pan-EC marker Enhanced discrimination accuracy Lack of commercial antibody availability
Prox-1/CD31 antibodies LEC/Pan-EC marker Enhanced discrimination accuracy Lack of commercial antibody availability
LEC¼lymphatic endothelial cells; 50NA¼50nucleotidase; LYVE-1¼lymphatic vessel endothelial hyaluronan receptor-1; BEC¼blood vascular endothelial marker; Pan-EC
marker¼pan-endothelial cell marker.
Lymphangiogenesis in gastrointestinal malignancy
SE Duff et al
427
British Journal of Cancer (2003) 89(3), 426–430 & 2003 Cancer Research UKstudies (Table 2). There are no studies that have examined the role
of VEGF-D in gastric cancer.
Immunohistochemical analysis of tumour tissue has demon-
strated that VEGF-C immunoreactivity is restricted to gastric
cancer cells and is observed diffusely throughout the cytoplasm
(Yonemura et al, 1999, 2001; Ichikura et al, 2001). The percentage
of gastric tumours that are positive for VEGF-C protein expression
varies from 26 to 51% (Table 2) (Yonemura et al, 1999; Ichikura
et al, 2001; Kabashima et al, 2001; Takahashi et al, 2002), although
this may be accounted for in part by the use of varying
methodology as discussed.
Lymphatic invasion and lymph node status correlate positively
with tissue expression of VEGF-C in gastric cancer (Yonemura
et al, 1999; Ichikura et al, 2001; Kabashima et al, 2001; Amioka
et al, 2002; Takahashi et al, 2002) (Table 2). In addition, positive
VEGF-C tissue expression in early gastric cancer (confined to the
mucosa or submucosa) was significantly associated with lymphatic
invasion, potentially helping to predict those individuals who
would benefit from more or less extensive surgical resections
(Kabashima et al, 2001). Similar associations have been demon-
strated concerning the expression of VEGF-C mRNA expression in
gastric cancer tissue. Malignant tissue expressed increased VEGF-
C mRNA compared with adjacent normal mucosa (47 vs 13%
(Yonemura et al, 1999); 55 vs 13% (Yonemura et al, 2001)).
Furthermore, positive lymph node status, lymphatic and venous
invasion were also associated with expression of VEGF-C mRNA
(Yonemura et al, 1999).
The clinical impact of the association between VEGF-C
expression and prognosis is not fully understood (Table 2).
Nonsignificant trends towards reduced survival in VEGF-C
expressing gastric cancers have been found (Ichikura et al,
2001). However, in 117 patients with gastric cancer, Yonemura
et al (1999) demonstrated that high levels of VEGF-C expression
were associated with poorer prognosis and decreased survival.
Further significant differences in survival associated with VEGF-C
status have been reported by Takahashi et al (2002) in a group of
65 cancer patients. A potentially important clinical finding of this
study was the negative correlation of dendritic cell density with
VEGF-C expression in the tumour. The effect of VEGF-C on
survival may be due, in part, to its regulatory function on dendritic
cells with potential reduced immunosurveillance of the tumour
(Kabashima et al, 2001).
In contrast to VEGF-C, VEGFR3 immunoreactivity in gastric
tumours is restricted to endothelial cells of mucosal and
submucosal vessels that are regarded primarily as lymphatic
vessels but also to a very few small blood vessels. Consequently, the
majority of VEGFR3-positive vessels in gastric cancer are
considered as lymphatics (Yonemura et al, 1999, 2001). A positive
correlation between VEGFR3 and VEGF-C mRNA expression was
seen in gastric cancer tissue specimens (Yonemura et al, 1999,
2001). Microvessel counts for VEGFR3 positive vessels showed a
significant increase in VEGF-C mRNA positive tumours compared
to VEGF-C mRNA negative tumours (6.9676.05 vs 2.1672.00,
Po0.001). However, there was no overall increase in the VEGFR3
positive vessel count in tumour stroma compared with normal
gastric mucosa when both VEGF-C mRNA positive and negative
tumours were considered together (4.6275.85 vs 2.4871.64,
P¼0.067) (Yonemura et al, 2001). Similar increases in VEGFR3
positive vessel counts are seen in gastric cancers that are lymph
node positive, show lymphatic invasion or are poorly differen-
tiated (Yonemura et al, 2001).
In summary, in gastric cancer, expression of VEGF-C mRNA is
higher in tumour than in normal mucosa. Vascular endothelial
growth factor-C mRNA and immunohistochemically detected
tissue expression of the protein in gastric cancer correlate with
lymphatic invasion and lymph node metastasis and in some
studies, venous invasion with reduced survival (Table 2). Vascular
endothelial growth factor receptor 3 expression is mainly found on
lymphatic vessels in gastric tumours and VEGFR3 mRNA levels
and tissue expression parallel that of VEGF-C. These results
suggest that VEGF-C and VEGFR3 act together in a paracrine
fashion in the microenvironment of the gastric tumour.
Oesophageal cancer
Oesophageal cancer has a poor prognosis, which is dependent on
the presence of lymph node metastases. Limited and conflicting
evidence exists for the role of VEGF-C in oesophageal cancer and
no research is available concerning VEGF-D. Kitadai et al (2001)
analysed the relationship between the expression of VEGF-C and
clinicopathological characteristics in oesophageal squamous cell
carcinoma. In vitro analysis demonstrated that four of the five
oesophageal carcinoma cell lines studied expressed VEGF-C
mRNA. Ex vivo analysis confirmed VEGF-C mRNA to be present
in eight of the 12 oesophageal squamous carcinomas. In a further
48 archival specimens, 39.6% showed positive immunohistochem-
ical staining for VEGF-C, which correlated with stage of disease,
lymphatic invasion, venous invasion and lymph node metastasis
(Po0.01) and depth of tumour invasion (Tumour in situ (Tis) vs
T1, Po0.05; Tis vs T2, T3, Po0.01). Interestingly, the number of
blood vessels detected by immunohistochemical staining for CD34
was significantly higher in the VEGF-C-positive tumours than the
VEGF-C-negative tumours (Kitadai et al, 2001), suggesting that
VEGF-C may be involved in both angiogenic and lymphangiogenic
Table 2 Immunohistochemical examination of VEGF-C expression in gastrointestinal malignancy
Clinicopathological associations of increased
VEGF-C expression with regard to
Tumour type
Number
of cases
VEGF-C
IHC
positive
(%)
Lymphatic
invasion
Venous
invasion
Lymph node
metastasis
Prognosis
Reference
Oesophageal SCC 48 40 Po0.01 Po0.01 Po0.01 NA Kitadai et al (2001)
Oesophageal SCC 71 54 P¼0.51 P¼0.092 P¼0.085 P¼0.80 Noguchi et al (2002)
Gastric adenocarcinoma 117 26 Po0.05 Po0.01 Po0.05 Po0.001 Yonemura et al (1999)
Gastric adenocarcinoma 76 45 P¼0.04 P¼0.07 NS NS trend Ichikura et al (2001)
Early gastric adenocarcinoma 105 29 P¼0.02 NS increase NS increase NA Kabashima et al (2001)
Gastric adenocarcinoma 65 51 Po0.05 NS Po0.05 Po0.01 Takahashi et al (2002)
Gastric adenocarcinoma 139 32 Po0.05 NS Po0.05 NA Amioka et al (2002)
Advanced colorectal
adenocarcinoma
152 47 Po0.01 Po0.01 Po0.01 Po0.05 Furodoi et al (2002)
Colorectal adenocarcinoma 99 56 Po0.01 NS Po0.01 NS trend Akagi et al (2000)
Colorectal adenocarcinoma 59 35 NS NA NS NA George et al (2001)
SCC¼squamous cell carcinoma; IHC¼immunohistochemistry; NS¼nonsignificant; NA¼not assessed. Values in bold type indicate statistically significant results.
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numbers of oesophageal squamous carcinomas for immunohisto-
chemical expression of VEGF-C protein, but did not report a
significant association between the expression of the cytokine and
any clinicopathological factor other than histological grade
(Noguchi et al, 2002) (Table 2).
Vascular endothelial growth factor-C expression is associated
with neoplastic progression in the oesophageal mucosa. Using
immunohistochemical detection, normal oesophageal mucosa does
not express VEGF-C although there is an increase in expression in
Barrett’s epithelium as it progresses through dysplasia to
adenocarcinoma, and this is paralleled by a similar increase in
VEGFR3 expression on lymphatic vessels (Auvinen et al, 2002).
Colorectal cancer
Colorectal cancer is similar to oesophageal cancer, in that the role
of VEGF-C is less well understood than in gastric carcinoma.
Conflict also exists as to the role of VEGF-D. Recent publications
illustrate conflicting results regarding protein and gene expression
in relation to clinicopathological measures (Table 2).
With respect to VEGF-C expression, several authors have
demonstrated associations between growth factor expression and
poor clinicopathological outcome (Akagi et al, 2000; Furodoi et al,
2002). Immunohistochemical detection of VEGF-C expression at
the deepest invasive site of colorectal carcinoma was found in 47%
of 152 advanced tumours. Expression correlated with lymphatic
and venous invasion, lymph node status, Dukes’ stage, liver
metastasis, depth of invasion, poorer histological grade and
microvessel density (Furodoi et al, 2002). Vascular endothelial
growth factor-C expression and lymph node metastasis were
independent prognostic factors for 5-year survival on multivariate
analysis (odds ratio (OR) 9.10, P¼0.0272 and OR 8.52, P¼0.0322,
respectively). The study also emphasised the paracrine nature of
the interaction between VEGF-C and the tumour microenviron-
ment and the positive relationship between VEGF-C and tumour
angiogenesis (Furodoi et al, 2002). Similar associations between
tissue VEGF-C expression and clinicopathological factors have
been described by Akagi et al (2000) with consistent patterns of
VEGF-C expression in involved lymph nodes and primary
tumours, although in this study only a nonsignificant trend
towards decreased survival was identified in VEGF-C positive
groups.
Contradictory evidence exists concerning the role of VEGF-C in
lymphatic metastasis in colorectal cancer. Studies examining
mRNA levels of various VEGF family members tend to show a
lack of association with clinicopathological factors. George et al
(2001) showed an increase in VEGF-A and VEGF-C mRNA in
carcinomas (P¼0.006 and P¼0.004, respectively) but not in
colonic polyps (P¼0.22 and 0.5, respectively). No association was
found between the increased level of VEGF-C mRNA and lymph
node status, although a positive relationship existed between
positive lymph nodes and VEGF-A mRNA expression. Patterns of
VEGF-C mRNA expression were similar in the primary tumour
and lymphatic metastases. The mRNA findings of the study were
confirmed by immunohistochemistry, which showed no correla-
tion between positive staining for VEGF-A, VEGF-C or VEGF-D
and lymphatic spread (George et al, 2001). Further analyses of
VEGF family mRNA levels in the adenoma–carcinoma sequence
showed that of VEGF-A, VEGF-B and VEGF-C, only VEGF-A
mRNA levels were consistently raised in invasive malignancy and
this became apparent early on in disease progression, as levels
were elevated to a similar extent in tumours with and without
lymph node metastases or distant spread (Andre et al, 2000).
A few studies have focussed on the role of VEGF-D in colorectal
malignancy with conflicting results. Tumour expression, assessed
by RT-PCR, of VEGF-D mRNA was less than in normal tissue
(George et al, 2001), while White et al (2002) found higher levels of
VEGF-D protein expression in cancers detected by immunohis-
tochemistry. The increased VEGF-D protein levels detected were
associated with lymph node involvement and reduced overall and
disease-free survival (White et al, 2002).
The role of VEGF-D within tumours is not well understood, but
it has been suggested that VEGF-D may act competitively as an
antagonist to the other VEGF family members. George et al (2002)
postulated that a reduction in VEGF-D levels in the adenoma–
carcinoma sequence allowed the more potent angiogenic cytokines
VEGF-A and VEGF-C to bind more readily to the signalling
receptors VEGFR2 and VEGFR3. The balance between various
members of the VEGF family, their relative levels within a tumour,
the extent of proteolytic processing and receptor availability may
be important in determining tumour behaviour. The importance of
the balance between VEGF-C and VEGF-D is illustrated in lung
adenocarcinoma, where a low ratio of VEGF-D:VEGF-C (i.e., low
VEGF-D and high VEGF-C) is associated with lymph node
metastasis and lymphatic invasion (Niki et al, 2000).
Upregulation of cytoplasmic VEGFR3 protein expression has
been demonstrated immunohistochemically in colorectal cancer
tissue specimens and increased expression was associated with
poorer overall survival (Po0.05) (Witte et al, 2002). This again
demonstrates the potent paracrine nature of the interaction
between the cytokines and their receptor in the microenvironment
of the tumour.
In conclusion, conflicting reports exist for the precise involve-
ment of VEGF-C and VEGF-D in lymphatic invasion, lymph node
metastasis and prognosis in colorectal cancer. The importance of
appropriate sampling and consistency in methodology of im-
munohistochemical staining and scoring are fundamental to
interpretation and comparison between studies.
CONCLUSIONS
Lymphangiogenesis is an exciting area of research in cancer
biology. The growth factors VEGF-C and D are involved in this
process and possess angiogenic and lymphangiogenic properties.
The expression of lymphangiogenic factors is increased in many
human malignancies and this is illustrated with respect to
malignancies of the gastrointestinal tract. In gastric adenocarci-
noma, lymphatic metastasis and lymphatic invasion are enhanced
by increased expression of VEGF-C. The precise role for VEGF-C
in colorectal and oesophageal squamous malignancy and VEGF-D
in other tumours is not clearly understood, but is clearly important
at a paracrine level. Further studies using combinations of new
lymphatic markers and functional assays will help clarify the
influence of these and other cytokines in the future. However, an
essential requirement to allow comparison between studies is the
development of consistent experimental methodology. This must
include the use of antibodies of defined specificity, consistent
immunohistochemical protocols with appropriate use of controls
and widespread consensus in scoring techniques. Further under-
standing of the function and actions of VEGF-C and VEGF-D is
required to optimise therapeutic strategies, avoiding unwanted
side effects, in the treatment of benign and malignant disease.
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